J&J Eprex Stability Improvements Planned In Response To Aplasia Incidence

Johnson & Johnson will seek alternative stabilizers for its erythropoietin Eprex in response to reports of pure red cell aplasia following the removal of human serum albumin from the product formula

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet